Leading International Investment Research, Edison Investment Research

Edison Investment Research

Leading International Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Equity Bottom-Up

<p>Sierra Oncology held an investor meeting on 27 February 2018, which provided a comprehensive update on its programs. The most immediately impactful data was a favourable safety profile reported from the ongoing Phase I/II clinical trials (monotherapy and gemcitabine combination). It was announced that the monotherapy trial had entered the Phase II dose-expansion portion of the trial and that the combination study will enter this phase in Q218. Preliminary results for this trial are expected in Q418.</p>

Sierra Oncology held an investor meeting on 27 February 2018, which provided a comprehensive update on its programs. The most immediately impactful data was a favourable safety profile reported from the ongoing Phase I/II clinical trials (monotherapy and gemcitabine combination). It was announced that the monotherapy trial had entered the Phase II dose-expansion portion of the trial and that the combination study will enter this phase in Q218. Preliminary results for this trial are expected in Q418.

Sierra Oncology - Progress with ongoing trials and future plans

<p>We are initiating coverage on Sierra Oncology, a drug developer targeting the DNA damage response (DDR) network to treat cancer. The company has two Phase I trials with SRA737 targeting checkpoint kinase 1 (Chk1) in patients with genetic tumor types expected to respond to the drug. Inhibition of Chk1 is lethal in cells with defective p53 (among others), one of the most common cancer mutations, and also enhances the response to chemotherapy. Sierra also has the cell division cycle 7 (Cdc7) inhibitor SRA141 in preclinical testing. Our initial valuation is $206m or $3.95/share.</p>

We are initiating coverage on Sierra Oncology, a drug developer targeting the DNA damage response (DDR) network to treat cancer. The company has two Phase I trials with SRA737 targeting checkpoint kinase 1 (Chk1) in patients with genetic tumor types expected to respond to the drug. Inhibition of Chk1 is lethal in cells with defective p53 (among others), one of the most common cancer mutations, and also enhances the response to chemotherapy. Sierra also has the cell division cycle 7 (Cdc7) inhibitor SRA141 in preclinical testing. Our initial valuation is $206m or $3.95/share.

Expanding on a proven class of anti-cancer drugs

United States

Sierra Oncology, Inc. operates as a clinical-stage oncology company. The Company develops therapies that target deoxyribonucleic acid (DNA) to treat patients with cancers and other complex genetic diseases. Sierra Oncology serves customers in North America.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Sierra Oncology (SRRA US)

Sierra Oncology - Progress with ongoing trials and future plans

Sierra Oncology held an investor meeting on 27 February 2018, which provided a comprehensive update on its programs. The most immediately impactful...

Edison Investment Research

Expanding on a proven class of anti-cancer drugs

We are initiating coverage on Sierra Oncology, a drug developer targeting the DNA damage response (DDR) network to treat cancer. The company has...

Edison Investment Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)